Categories
press-releases

Shanton Pharma Raised $31.2 Million in Series A+ Financing

– Established China Biotechnology Company with Global Headquarters in the United States

– Proceeds will advance clinical development of SAP-001 clinical trials for hyperuricemia and gout

Based in Shanghai, Shanton Pharma is a private clinical-stage biotechnology company dedicated to the research, development and commercialization of innovative medicines in areas of unmet medical need, closed a $31.2 million Series A+ financing in December of 2020.

The proceeds will be used to accelerate the progress of the clinical program SAP-001, a treatment for hyperuricemia and gout and to further expand its preclinical or clinical pipeline.

The round was co-led by Begion Limited, BioTrack Capital and Longpan Health Medical Investment Fund with participation from BC Tophiaway Limited, Hanium Industries Limited, and HT Capital MTech Venture CF I L.P.

Categories
press-releases

Shanton Pharma Meets Primary Endpoint for Phase 2 Study of SAP-001

The Shanton Pharma Phase 2 study evaluating its investigational product SAP-001, an oral, small molecule, achieved its primary endpoint. In the trial, SAP-001 significantly reduce uric acid /eliminate the risk of acute gout attack/reduce and/or eliminate tophi. SAP-001 was well tolerated.